X
Please Wait
Applying Filters...
1. 17 Desoxymethasone
2. 17-desoxymethasone
3. A 41304
4. A-41304
5. A41304
6. Deoxydexamethasone
7. Desoxi
8. Desoxymethasone
9. Flubason
10. Ibaril
11. Stiedex
12. Topicort
13. Topicorte
14. Topisolon
1. 382-67-2
2. Desoxymethasone
3. Topicort
4. Desoximetasona
5. Desoximetasonum
6. Topicort Lp
7. Desoxymetasone
8. Hoe-304
9. Hoe 304
10. A-41-304
11. Deoxymethasone
12. 9-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
13. R-2113
14. (8s,9r,10s,11s,13s,14s,16r,17s)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6h-cyclopenta[a]phenanthren-3-one
15. Chebi:691037
16. Dexamethasone Impurity F
17. R 2113
18. 4e07gxb7au
19. Esperson
20. Mls000028654
21. 17-deoxymethansone
22. 17-desoximethasone
23. A-41304
24. 9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
25. Nsc-759189
26. (8s,9r,10s,11s,13s,14s,16r,17s)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
27. 140218-14-0
28. Ncgc00023648-03
29. Flubason
30. J83.644c
31. Smr000058856
32. Stiedex
33. Ibaril
34. (11beta,16alpha)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
35. Dsstox_cid_25647
36. Dsstox_rid_81025
37. Dsstox_gsid_45647
38. Desossimetasone
39. A 41304
40. Topicort (tn)
41. Cas-382-67-2
42. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, Labeled With Tritium, (11beta,16alpha)-
43. Desossimetasone [dcit]
44. A 41-304
45. Desoximetasone (usp/inn)
46. Unii-4e07gxb7au
47. Desoximetasonum [inn-latin]
48. Desoximetasona [inn-spanish]
49. Einecs 206-845-3
50. Desoximetasone [usan:usp:inn:ban]
51. Brn 2228097
52. Opera_id_52
53. Desoximetasone [mi]
54. Schembl4214
55. Chembl1766
56. Desoximetasone [inn]
57. Desoximetasone [jan]
58. Desoximetasone [usan]
59. Mls001076073
60. Mls001424230
61. Desoximetasone [vandf]
62. Desoximetasone [mart.]
63. Gtpl7067
64. Desoximetasone [usp-rs]
65. Desoximetasone [who-dd]
66. Dtxsid3045647
67. 9-fluoro-11.beta.,21-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione
68. Hms2052c15
69. Hms2236h07
70. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-
71. Zinc4212854
72. Desoximetasone [orange Book]
73. Tox21_110889
74. Bdbm50103622
75. Desoximetasone [usp Impurity]
76. Mfcd00083301
77. S5685
78. Desoximetasone [usp Monograph]
79. 9-fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione
80. Akos030254657
81. Tox21_110889_1
82. Ccg-101120
83. Db00547
84. Nc00370
85. Nsc 759189
86. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11beta,16alpha)-
87. Ncgc00023648-04
88. As-15787
89. Hy-17570
90. D5515
91. Dexamethasone Impurity F [ep Impurity]
92. D03697
93. T72402
94. 382d672
95. Q385370
96. Q-200938
97. 9alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1.4-pregnadiene-3,20-dione
98. (1r,2s,10s,11s,13r,14s,15s,17s)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
| Molecular Weight | 376.5 g/mol |
|---|---|
| Molecular Formula | C22H29FO4 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 376.20498756 g/mol |
| Monoisotopic Mass | 376.20498756 g/mol |
| Topological Polar Surface Area | 74.6 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 757 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Desoximetasone |
| Drug Label | Topicort (desoximetasone cream USP) 0.05%, Topicort (desoximetasone cream USP) 0.25%, and Topicort (desoximetasone gel USP) 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of prim... |
| Active Ingredient | Desoximetasone |
| Dosage Form | Gel; Ointment; Cream |
| Route | Topical |
| Strength | 0.05%; 0.25% |
| Market Status | Prescription |
| Company | Glenmark Generics; Fougera Pharms; Versapharm; Perrigo New York |
| 2 of 4 | |
|---|---|
| Drug Name | Topicort |
| PubMed Health | Desoximetasone (On the skin) |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong, Dermatological Agent |
| Drug Label | Topicort (desoximetasone cream USP) 0.05%, Topicort (desoximetasone cream USP) 0.25%, and Topicort (desoximetasone gel USP) 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of prim... |
| Active Ingredient | Desoximetasone |
| Dosage Form | Ointment; Cream; Spray; Gel |
| Route | Topical |
| Strength | 0.05%; 0.25% |
| Market Status | Prescription |
| Company | Taro; Taro Pharms North |
| 3 of 4 | |
|---|---|
| Drug Name | Desoximetasone |
| Drug Label | Topicort (desoximetasone cream USP) 0.05%, Topicort (desoximetasone cream USP) 0.25%, and Topicort (desoximetasone gel USP) 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of prim... |
| Active Ingredient | Desoximetasone |
| Dosage Form | Gel; Ointment; Cream |
| Route | Topical |
| Strength | 0.05%; 0.25% |
| Market Status | Prescription |
| Company | Glenmark Generics; Fougera Pharms; Versapharm; Perrigo New York |
| 4 of 4 | |
|---|---|
| Drug Name | Topicort |
| PubMed Health | Desoximetasone (On the skin) |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong, Dermatological Agent |
| Drug Label | Topicort (desoximetasone cream USP) 0.05%, Topicort (desoximetasone cream USP) 0.25%, and Topicort (desoximetasone gel USP) 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of prim... |
| Active Ingredient | Desoximetasone |
| Dosage Form | Ointment; Cream; Spray; Gel |
| Route | Topical |
| Strength | 0.05%; 0.25% |
| Market Status | Prescription |
| Company | Taro; Taro Pharms North |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA Label
Like other topical corticosteroids, desoximetasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Desoximetasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC03 - Desoximetasone
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07X - Corticosteroids, other combinations
D07XC - Corticosteroids, potent, other combinations
D07XC02 - Desoximetasone
Absorption
Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Route of Elimination
Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.Pharmacokinetic studies in men with Desoximetasone Cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% 2.9% excretion in urine (4.1% 2.3%) and feces (1.1% 0.6%)
Metabolized, primarily in the liver, and then excreted by the kidneys.
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. This is achieved first by the drug binding to the glucocorticoid receptors which then translocates into the nucleus and binds to DNA causing various activations and repressions of genes. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Market Place
